Dual energy CT - a possible new method to assess regression of rectal cancers after neoadjuvant treatment by Al-Najami, Issam et al.
                                                              
University of Dundee
Dual energy CT - a possible new method to assess regression of rectal cancers after
neoadjuvant treatment
Al-Najami, Issam; Drue, Henrik C.; Steele, Robert; Baatrup, Gunnar
Published in:
Journal of Surgical Oncology
DOI:
10.1002/jso.24761
Publication date:
2017
Document Version
Peer reviewed version
Link to publication in Discovery Research Portal
Citation for published version (APA):
Al-Najami, I., Drue, H. C., Steele, R., & Baatrup, G. (2017). Dual energy CT - a possible new method to assess
regression of rectal cancers after neoadjuvant treatment. Journal of Surgical Oncology, 116(8), 984-988.
https://doi.org/10.1002/jso.24761
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
 Dual Energy CT - a possible new method to assess regression of rectal cancers after 
neoadjuvant treatment. 
 
 
Authors: Issam Al-Najami MD.1,2, Henrik Christian Drue MD.3 , Robert Steele Ph.D.4, 
Gunnar Baatrup Ph.D.1,2 
Corresponding author: Issam al-Najami, Valdemarsgade 53, 5700 Svendborg, 
Denmark. Tel. No. +45451909297 
 
Authors’ affiliation:  
1. Department of surgery, Odense University Hospital, Svendborg, Denmark 
2. Department of Clinical Research, University of Southern Denmark.  
3. Department of Radiology, Odense University Hospital, Svendborg, Denmark. 
4. Centre for Research into Cancer Prevention and Screening, Cancer Division, 
Medical Research Institute, Ninewells Medical School, Dundee, UK24608398 
Funding: The Danish Cancer Society, the Research Foundation of the Region of 
Southern Denmark, the Research Foundation of the University of Southern Denmark, 
and the Research Foundation of Odense University Hospital. 
Key words: Pathological response, effective-Z, tumour regression. 
 
This is the peer reviewed version of the following article: ’ Dual energy CT - a possible new 
method to assess regression of rectal cancers after neoadjuvant treatment’, Journal of Surgical 
Oncology, which has been published in final form at http://dx.doi.org/ 10.1002/jso.24761. This 
article may be used for non-commercial purposes in accordance with Wiley Terms and 
Conditions for Self-Archiving. 
 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Running head: DECT measurements of tumour regression  
 
 
Synopsis: 
The assessment of rectal tumor regression grade is essential for offering a 
tailormade treatment to rectal cancer patients to avoid over-treatment or under-
treatment. Thus far, no assessement tool has proven to be optimal, however, dual 
energy CT is a new imaging technique with promising potential. 
 
 
List of abbreviations: 
 
DECT : Dual Energy CT 
TRUS : Trans Rectal UltraSound 
DEI : Dual Energy Index  
DER : Dual Energy Ratio 
RCRG : Rectal Cancer Regression Grade 
HU : Hounsfield Unit 
CRT : Chemo Radio Therapy 
nCRT: Neoadjuvant chemoradio therapy 
pCR : pathologic Complete Response 
cCR : complete Clinical Response  
ypT : Post radiochemotherapy T stage 
TME : Total Mesorectal Excision 
TEMS: Transanal Endoscopic Micro Surgery 
keV : kilo electron Volt 
ROI : Region Of Interest 
  
 3 
Abstract 
Background and objectives 
 The Measurement of tumour regression after neoadjuvant oncological treatment 
has gained increasing interest because it has a prognostic value and because it may 
influence the method of treatment in rectal cancer. The assessment of tumour 
regression remains difficult and inaccurate with existing methods. Dual Energy 
Computed Tomography (DECT) enables qualitative tissue differentiation by 
simultaneous scanning with different levels of energy.  
We aimed to assess the feasibility of DECT in quantifying tumour response to 
neoadjuvant therapy in loco-advanced rectal cancer.  
 
Methods 
 We enrolled eleven patients with histological and MRI verified loco-advanced rectal 
adenocarcinoma and followed up on them prospectively. All patients had one DECT 
scanning before neoadjuvant treatment and one twelve weeks after using the 
spectral imaging scan mode. DECT analysing tools were used to determine the 
average quantitative parameters; effective-Z, water- and iodine-concentration, Dual 
Energy Index (DEI) and Dual Energy Ratio (DER). These parameters were compared 
to the regression in the resection specimen as measured by the pathologist. 
 Results 
Changes in the quantitative parameters differed significantly after treatment in 
comparison with pre-treatment, and the results were different in patients with 
different CRT response rates.  
Conclusion 
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DECT might be helpful in the assessment of rectal cancer regression grade after 
neoadjuvant treatment.  
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Introduction 
 
Neoadjuvant chemo-radiotherapy (nCRT) given to patients with locally advanced 
rectal cancer improves local disease control after radical surgery and leads to 
variable degrees of tumour down staging1. Fifteen to twenty percent of the patients 
who undergo nCRT have a histo- pathological complete response (pCR) after 8 – 12 
weeks in which no residual cancer is reported at histological examination of the 
resection specimen2. A pCR following nCRT is associated with excellent long-term 
survival with low rates of local recurrence and metastasis making it an independent 
predictor of prognosis 2.  
Patients with comorbidity may benefit in terms of treatment-related morbidity and 
mortality from avoiding major rectal resections. Ongoing trials indicate that watchful 
waiting may become an option for patients with pCR and that some patients with 
partial response might be candidates for local excision instead of rectal excision or 
extirpation3, 4 . Therefore it is of importance to be able to validate pCR with high 
accuracy after nCRT. Watchful waiting without surgery after pCR is still experimental 
but good long-term results have been reported 2. Complete clinical response (cCR), 
often defined as no tumour identified at clinical examination post CRT, has been 
used to identify candidates for alternatives to major surgery. The most frequently 
used method for preoperative examination is digital rectal examination in 
combination with endoscopy, or high frequency endo-rectal ultrasound, and MRI. 
But there is no generally accepted standard for evaluating the response to nCRT, and 
previous studies show poor correlation between cCR and pCR. In a study from 2009, 
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transrectal ultrasound (TRUS) correctly classified the histological T stage in only 46% 
of tumours after neoadjuvant chemo-radiation 5. A study from 2005 using MRI 
correctly classified 52 % of tumours, with various ypT-stages, with 38 % and 10.0 % 
over and under-staged respectively 6. 
As demonstrated in earlier studies, simultaneous scanning with 2 x-ray beams with 
variable energy levels (DECT) allows for differentiation between benign and 
malignant tissue7. By scanning with varying energy levels, the patients can be 
exposed to a lower radiation dose using DECT compared to regular CT.  
DECT allows for reduction in the image blurriness through an iterative reconstruction 
process which may enable dose reduction during scanning while maintaining 
diagnostic image quality. In clinical practice, the use of DECT may reduce CT patient 
dose depending on the clinical task, patient size and anatomical location of the 
region of interest, making its clinical implementation favorable.  
Effective-z is the main outcome measure in DECT. The z value is a surrogate of the 
atomic mass and is therefore unique to different elements such as iodine or calcium, 
but it will vary in mixtures of material as in human tissue such as rectal tumors 
whereby the average atomic mass of a mixture represents the effective-z.  
The objective of this feasibility study was to identify the best DECT unique 
quantitative parameters in the assessment of tumour regression, and to investigate 
whether DECT could be useful in the evaluation of tumour regression in patients 
with rectal cancer after neoadjuvant chemo-radiation.  
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Materials and methods 
 
Patients  
DECT images from 11 adult patients with biopsy and MRI verified rectal 
adenocarcinoma were prospectively included and analysed. All of them underwent 
neoadjuvant therapy according to national guidelines. All 11 patients were staged as 
T3 or T4 disease. Nine patients received radiation therapy consisting of 50 Gy in 25 
fractions in combination with Capecitabine 825 mg/m2 bid. Two patients received 
radiation therapy but did not complete their chemotherapy. A DECT scan and a MRI 
scan was performed before and eight weeks after completing CRT (12 weeks after 
the initiation of nCRT). TME was made 2-4 weeks after the follow-up MRI and DECT 
scan. 
 
 
 
Dual Energy CT 
All patients underwent 2 series of single source DECT scanning. The patients were 
given iodine based contrast agent (Omnipaque®, GE Healthcare®, 300mg/ml) and 
scanned with a DECT scanner (GE Discovery CT750 HD, GE Healthcare®, Milwaukee, 
WI). The Technical details have been described above.7  
 
Imaging analysis, quantitative parameters  
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The images were analysed with integrated imaging analytic tools for quantitative 
assessment of the iodine and water concentration, effective-z, dual energy index, 
and the dual energy ratio. (See figure 1). 
A dedicated radiologist applied three circular regions of interest on each tumour on 
all DECT-scanning images. The three chosen ROIs were based on a macroscopic 
evaluation of the most representative images of the associated MRI scan.  
 
 
Histopathology 
A dedicated pathologist assessed the RCRG after resection and scored the tumour 
according to 5 RCRG levels8. RCRG 1: the tumour is either sterilised or contains only 
microscopic foci of adenocarcinoma. RCRG 2: marked fibrosis, but with macroscopic 
tumour still present. RCRG 3: little or no fibrosis in the presence of abundant 
macroscopic tumour which contains less than 50 % cancer cells. RCRG 4: little or no 
fibrosis in the presence of abundant macroscopic tumour which contains more than 
50 % cancer cells. RCRG 5: no or little evidence of tumour shrinkage8  9. RCRG 1 was 
considered a complete response, RCRG 2+3 a partial response, and RCRG 4+5 as 
poor/ no response. 
 
Ethics 
This study has been conducted according to the principles established in the Helsinki 
declaration of October 2000. The study was approved by the Danish ethical 
committee of medical research with the registration number s-20130093. 
ClinicalTrials.gov ID: NCT02592304.  
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Statistics 
The differences in the quantitative parameters within the different RCRG groups are 
given as means and standard deviations. An F-test is used to test the differences in 
means before and after chemo-radiation stratified to different RCRG groups, with a 
null hypothesis of equality. A P value of <0.05 was regarded as significant. 
 
 
 
Results 
Diagnostic performance of the quantitative parameters 
Within the feasibility settings of this study, we aimed to determine the best 
quantitative unique DECT parameter for further assessment of the RCRG. As 
illustrated in Table 1 and figure 2, changes of the effective Z value was consistently 
correlated to the different RCRG groups. The change in the other parameters was 
similar to that of effective Z, but in a less consistent manner and with larger standard 
deviations (table 1). Only the effective Z value showed a high degree of correlation 
to the respective RCRG group with a correlation coefficient r2= 0.96, making it the 
parameter of choice in this study. 
 
Eleven patients were enrolled in the study. Extracted and calculated data from the 
Regions of interest were analysed and the change within each response group from 
before and after treatment is shown in table 1. The pathology results consisted of 2 
complete responders, 6 partial responders and 3 non-responders. 
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The effective Z pre- and post CRT compared to CRT response 
The mean effective Z of the pre-CRT DECT scans of all the enrolled patients was 8.82 
(see table 1). 
In relation to the complete responders the mean effective Z value was 8.31. 
Compared to the effective Z value pre-CRT there was a decrease of 7.0 % (p < 0.05).  
For the partial responders the mean effective Z value was 8.59 compared to the 
effective Z value obtained before treatment corresponding to a decrease of 3 % (p < 
0.05). In the group of non-responders there was no significant change in the 
effective-z. The mean value was 8.83 compared to the pre-CRT effective Z value and 
we obtained a change of 0.3 % (p > 0.05). See figure 3+4 and table 1. 
 
We demonstrated a 6 % decrease in the effective Z post CRT for complete 
responders (8.31) compared to non-responders (8.83).  
 
Discussion 
The aim of this feasibility study was to investigate whether DECT could measure and 
perhaps quantify the tumour regression grade in patients with loco-advanced rectal 
cancer by comparing DECT scanning before and after neoadjuvant treatment. We 
also compared the DECT unique effective Z post CRT in patients with different 
response to nCRT to assess the difference in the tumour regression grade.  
The assessment of tumour regression is today based on a specific dedication to 
rectal cancer staging imaging. This imaging is often prone to the imaging modality 
dedication and the results of the staging are often operator dependent. One 
advantage of DECT is that it would be suitable for all centers and also less dedicated 
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MRI centers dealing with rectal cancer as the technique does not require investment 
in costly equipment but can be added to regular clinical CT scanners by software 
installation. It also has the potential of decreasing operator dependency by 
measuring objective quantitative parameters. 
 
As shown in Table 1, all parameters in RCRG 1 had reduced values except for the 
water concentration parameter. As expected, the largest changes in the quantitative 
parameters were observed in the group with the highest regression grade. It is of 
interest that the changes were seen both in the measurements of the material 
composition being the effective-z  and the iodine concentration, but also in the 
measurements based on the Hounsfield units and therefore being based on a 
difference in the materials attenuation. The fact that the technique enables 
differentiating materials in two different ways reduces the observer variability 
compared to MRI and TRUS. In addition to the objective information obtained from 
DECT images, it has the potential to improve image quality over conventional 
imaging techniques due to enhanced material separation. 
By altering the energy levels of the image analysis it is not only possible to conduct 
the measured parameters, as was the focus of this study, but it is also possible to 
enhance certain types of materials of interest. This enhancement can be pointed out 
by using a color overlay based on material separation marking the area of interest 
that contains the material of interest, i.e. iodine figure 1 image E+F. 3D views are 
also obtainable to view the region of interest from different angles  figure 1 image 
G+H.Even though the variability is reduced it does play a role in the determination of 
the ROIs in the DECT analysis. ROIs includes the supposed region of the highest 
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tumor attenuation and may be prone to sampling error whereby  the lesion may not 
be completley included if the tumor shows irregular boarders. 
 Data from the quantitative parameters revealed a difference between complete and 
partial responders and effective-z, DER, DEI and iodine concentration which were all 
correlated to the pathological grading. We obtained smaller change the lower 
response rates were. In the non-responding tumours we saw almost no changes, and 
the most pronounced changes were demonstrated in the complete responding 
group.  
 
 Effective-Z has been useful in the determination of kidney stone composition10 but 
until present, effective-z has not been used in tumour characterization outside our 
unit. In a study of malignant pelvic lymph nodes, we found a lower effective-z value 
in benign compared to malignant lymph nodes, corresponding to the pattern we saw 
in the tumours with the highest regression grade. The measurement of the effective-
Z, DER and DEI could possibly support our earlier demonstrated benefits of DECT in 
benign/malignant differentiation and qualitative characterization of tumours7.  
When looking at figure 2 and table 1 we see a variation within each RCRG for DER, 
DEI and iodine measurements, and a wide range in the standard deviations 
suggesting a random distribution in each response group. Our study suggests that 
the effective-z could be used as an indicator to differentiate between a complete 
response and a no response in rectal cancer. However, the low number of subjects in 
this study does not allow for the exclusion of any of the other parameters in the 
quantification of tumour response to nCRT. 
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By observing a difference in the post CRT values of the effective Z value stratified in 
the different CRT response group we may be able to facilitate better allocation of 
patients to the most appropriate treatment. It might also facilitate more prompt 
surgical treatment to poor responders since they would not continue to experience 
tumour regression as would be the case with some of the partial responders11.  
Our results reveal a clear difference in the z-value between complete, partial and 
non-responders.  However, the number of patients included in this study is too small 
to conclude that we can reproducibly differentiate between different degrees of 
partial response. A larger study is needed and it is in preparation.  
Conclusions 
This study is the first to evaluate the utility of DECT in measuring tumour response to 
nCRT in rectal cancer. Our preliminary data indicates that the effective-Z value might 
enable   identifying and possibly quantifying pathological response.  
DECTs clinical applicability must be preceded by a comparison to gold standard in 
the assessment of rectal tumor regression being MRI. 
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Text to tables and figures 
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Table 1 describes the changes of the quantitative parameters stratified to the 
histopathological tumour regression grade. The percentages are the relative changes 
in the quantitative parameters from before to after CRT. 
RCRG = Rectal Cancer Regression Grade, CRT= Chemo-Radiation Therapy, DER = Dual 
Energy Ratio, DEI = Dual Energy Index, Eff Z= Effective Z, cPR= complete Pathological 
response, pPR= partial Pathological Response, nPR= no Pathological Response. 
 
Figure 1 DECT images and the corresponding analysis of the quantitative parameters. 
A. the implementation of the regions of interest (ROI) in the tumor for the 
assessment of the quantitative parameters, 3 ROIs was drawn in 3 different slices. B. 
Histogram of the measurement of the iodine concentrations in the ROIs, the three 
different colours represent 3 different ROIs in the same tumor. C. Histogram of the 
measurement of the effective Z value, the three different colours represent three 
different ROIs. D. Hounsfield unit curves, the slopes of the curves represent the DEI 
and DER. E. Represents a different visualization technique based on the 
enhancement of contrast media. F. Represents DECT image with a colour overlay to 
enhance the iodine concentration. G. Shows a DECT feature of 3D image 
reconstruction enhancing the tumor (red arrow) by enhancing vascularity. H. 3D 
image reconstruction, the tumor (red arrow) is enhanced by its iodine content. 
Figure 2 the relative changes in percentages for all the quantitative parameters. 
Notice the pattern of the effective-Z showing a relative change corresponding to the 
anticipated change in the tumour regression. Note there were no patients with a 
RCRG 5. 
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Figure 3 the correlation of the effective-Z to the RCRG, with a mean fitted line 
indicating a linear increase of the effective-Z with increasing RCRG. The correlation 
coefficient is given as R2= 0.98. 
Figure 4 illustrates the increase in effective Z with the decreasing response to chemo 
radiation therapy, by comparing the effective Z before chemo radiation therapy (pre-
CRT) to the three different rates of response.  
 
 
 
